

EMBARGO LIFTS: Thursday, Nov. 14 at 10:00 a.m. ET

Media Contact:

Monica McDonald

mmcdonald@rheumatology.org

Late Breaking Abstracts at ACR Convergence Push Research Boundaries, Advance Rheumatology and Patient Care

WASHINGTON— On the last day of [ACR Convergence 2024](#), late-breaking abstracts will be in the spotlight. The American College of Rheumatology will host a special session featuring five studies on topics ranging from significant improvement in lupus disease activity to the efficacy and safety of a Still's disease drug treatment for children and adults.

The featured late breakers are:

- **Abstract #L15:** LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial, which looks at new therapies to treat OA.
- **Abstract #L16:** Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial, which addresses reduction of B and T cell activation, among other things, with use of dapirolizumab pegol.
- **Abstract #L17:** Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial, that highlights the efficacy of CAR-T cells in a variety of autoimmune diseases.
- **Abstract #L18:** CCL19⁺ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis, which aims to understand the roles of diverse fibroblast subsets to elucidate the pathogenesis of fibrosis in systemic sclerosis.
- **Abstract #L19:** Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials that looks at safe treatments for a Still's disease complication.
- **Abstract #L20:** Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients, which evaluates the precision of a fully automated ultrasound scanning system.

The session is Tuesday, Nov. 19 at 8:00 a.m. in room 146AB of the Walter E. Washington Convention Center. View the full list of late-breaking abstracts [HERE](#).

###

About ACR Convergence

ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With hundreds of sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit the [ACR Convergence page](#), or join the conversation on X by following the official hashtag (#ACR24).

About the American College of Rheumatology

Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 9,600 physicians, health professionals, researchers and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit rheumatology.org.